Laetsch, Theodore
Zhang, Jie
Yang, Hongbo
Xie, Yanwen
Zhang, Dudan
Garrison, Louis
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Accepted: 26 March 2024
First Online: 29 April 2024
Declarations
:
: This study was supported by Novartis.
: Theodore Laetsch holds stock in Advanced Microbubbles; has consulting or advisory roles with Novartis, Aptitude Health, Jumo Health, Massive Bio, Medscape, AI Therapeutics, Jazz Pharmaceuticals, GentBio, Menarini, Pyramid Biosciences, Targeted Oncology, and Treeline Biosciences; and research funding from Lilly, Roche/Genentech, Taiho Oncology, Advanced Accelerator Applications/Novartis, Bristol-Myers Squibb, BioAtla, Hoffman-LaRoche, Pfizer, Bayer, and Turning Point Therapeutics. Louis Garrison reports having received consulting fees in the last 2 years for other research activities with a number of biopharmaceutical companies, including Novartis Gene Therapy, Pfizer, Astra-Zeneca, GSK, MSD, Eli Lilly, Genentech, Roche Molecular Systems, BioMarin, and UniQure. Jie Zhang is an employee of Novartis and owns stock/options. Hongbo Yang, Yanwen Xie, and Dudan Zhang are employees of Analysis Group, Inc., which has received consulting fees from Novartis.
: The data supporting this study were derived from publicly available literature (CEAs) or are contained in the article. Individual patient data from ELIANA will not be shared due to patient privacy.
: This was systematic literature review and economic analysis using public or previously collected, anonymized data. Thus, no ethical review was required. The study was conducted in accordance with the 1964 Declaration of Helsinki and its amendments.
: N/A.
: N/A.
: The model described in this study will not be publicly shared due to confidential information.
: All authors designed the study. HY, YX, and DZ performed the literature review and CEA analysis. All authors participated in revising the manuscript and have read and approved the final version.